Trial Profile
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary) ; DTaP poliovirus vaccine
- Indications Diphtheria; Meningococcal group B infections; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors Pfizer
- 30 May 2017 According to a Pfizer media release, the European Commission (EC) has approved TRUMENBA (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Results from this study supported the approval.
- 12 May 2014 According to the Pfizer media release, the trial results were presented at the 32nd Annual Meeting of the European Society for paediatric Infectious Disease (EPID 2014).
- 09 May 2014 Results of this trial were presented at European Society for paediatric Infectious Disease (EPID 2014).